- Home
- OPK vs APLT Comparison
OPK vs APLT Comparison
Compare OPK & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- APLT
- Stock Information
- Founded
- OPK 2007
- APLT 2016
- Country
- OPK United States
- APLT United States
- Employees
- OPK N/A
- APLT N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- APLT Health Care
- Exchange
- OPK Nasdaq
- APLT Nasdaq
- Market Cap
- OPK N/A
- APLT 44.0M
- IPO Year
- OPK 1995
- APLT 2019
- Fundamental
- Price
- OPK $1.35
- APLT $0.41
- Analyst Decision
- OPK Buy
- APLT Buy
- Analyst Count
- OPK 4
- APLT 7
- Target Price
- OPK $2.75
- APLT $6.10
- AVG Volume (30 Days)
- OPK 3.4M
- APLT 2.6M
- Earning Date
- OPK 08-06-2025
- APLT 08-06-2025
- Dividend Yield
- OPK N/A
- APLT N/A
- EPS Growth
- OPK N/A
- APLT N/A
- EPS
- OPK N/A
- APLT N/A
- Revenue
- OPK $689,408,000.00
- APLT $265,000.00
- Revenue This Year
- OPK N/A
- APLT $1,768.13
- Revenue Next Year
- OPK $7.80
- APLT $292.85
- P/E Ratio
- OPK N/A
- APLT N/A
- Revenue Growth
- OPK N/A
- APLT N/A
- 52 Week Low
- OPK $1.21
- APLT $0.30
- 52 Week High
- OPK $2.04
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- OPK 52.54
- APLT 58.87
- Support Level
- OPK $1.33
- APLT $0.32
- Resistance Level
- OPK $1.36
- APLT $0.36
- Average True Range (ATR)
- OPK 0.04
- APLT 0.04
- MACD
- OPK 0.01
- APLT 0.01
- Stochastic Oscillator
- OPK 73.33
- APLT 94.92
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.